Physician profile
Curt D Blacklock
NPI 1467465450
$10,606.56
in general payments reported to CMS, 2019-2025
34 companies · $1,504 in 2025
The $1,504 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $1,120 · 2021: $1,596 · 2022: $1,607 · 2023: $1,329 · 2024: $1,881 · 2025: $1,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,712 · Education: $1.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,712.30 |
| Education | $1.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,494.44 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,466.57 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $1,380.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,177.21 | 2019-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,067.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $641.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $589.15 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $505.59 | 2019-2025 | |
| Abbott Laboratories | $401.18 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $339.39 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $303.39 | 2019-2025 | Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $188.69 | 2019-2022 | |
| Exact Sciences Corporation | $130.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $122.05 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $107.84 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.08 | 2019-2022 | |
| Eisai INC. | $82.25 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $80.72 | 2024 | Voquezna |
| Scilex Pharmaceuticals INC. | $77.90 | 2022-2025 | Ztlido |
| Kowa Pharmaceuticals America, INC. | $48.14 | 2020 | |
| Dexcom, INC. | $38.47 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $32.29 | 2024-2025 | Intellis Adaptivestim, Closurefast |
| Tactile Systems Technology INC | $29.85 | 2025 | Nimbl, Flexitouch Plus |
| Shire North American Group INC | $29.21 | 2019 | |
| Endo Pharmaceuticals INC. | $25.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.37 | 2022 | |
| Shield Therapeutics INC | $18.78 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.66 | 2021 | |
| Sanofi Pasteur INC. | $17.78 | 2023 | |
| Radius Health, INC. | $17.38 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.96 | 2022 | |
| Seqirus USA INC | $15.54 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.21 | 2022 | |
| Linus Health, INC. | $13.07 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Blacklock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.